Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 1252

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Prof Paul Richardson speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the Phase 2 HORIZON study on the activity of melflufen in relaxed and refractory multiple myeloma (RRMM) patients with extramedullary disease.

He explains that the HORIZON study is so important because at the point that these patients relapse they are not only resistant to other treatment options, but the extramedullary component has to also be considered.

Prof Richardson concludes that the targeted cytotoxin melflufen is a promising treatment option for these high-risk patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation